Single User
£4350
PDF
92 pages

Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027


Non-Hodgkin Lymphomas (NHL) are a diverse group of blood cancers that develop from lymphocytes (a type of white blood cell). As the name suggests, they include all lymphomas except Hodgkin’s lymphoma. There are about 35 different subtypes of Non-Hodgkin Lymphomas. These are divided into two groups; aggressive (fast growing) and indolent (slow growing). NHL is also characterised by the cell type predominantly affected: either B cells or T cells.

This report provides the current incident population for Non-Hodgkin Lymphoma across 18  Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Non-Hodgkin Lymphoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Non-Hodgkin Lymphoma include:

  • Painless, swollen lymph nodes in the neck, armpits or groin
  • Abdominal pain or swelling
  • Chest pain, coughing or trouble breathing
  • Fatigue
  • Fever; night sweats
  • Pruritis (severe itching of the skin)
  • Unexplained weight loss

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Non-Hodgkin Lymphoma market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Non-Hodgkin Lymphoma and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Non-Hodgkin Lymphoma incident population.
  • Identify sub-populations within Non-Hodgkin Lymphoma which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Non-Hodgkin Lymphoma patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line incidence for Non-Hodgkin Lymphoma
  • Features of Non-Hodgkin Lymphoma patients
    • Staging of NHL patients
    • IPI score for NHL pat
    • Presence of Symptoms
  • B-cell lymphomas
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Follicular Lymphoma
    • Mantle cell Lymphoma
    • Burkitt’s Lymphoma
  • T-Cell Lymphoma
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Stages and modifiers of the Ann Arbour system
  • Risk assessment using the International Prognostic Index
  • Risk assessment using the FLIPI score
  • Incidence of Non-Hodgkin’s Lymphoma, total (000s)
  • Incidence of Non-Hodgkin’s Lymphoma, males (000s)
  • Incidence of Non-Hodgkin’s Lymphoma, females (000s)
  • Predominant cell type (000s)
  • Ann Arbour Stage of Non-Hodgkin’s Lymphoma (000s)
  • Ann Arbour Stage breakdown (stage I) (000s)
  • Ann Arbour Stage breakdown (stage II) (000s)
  • Ann Arbour Stage breakdown (stage III) (000s)
  • NHL patients by IPI Score, (000s)
  • NHL patients with systemic symptoms at diagnosis, (000s)
  • Incidence of B cell lymphoma, by main subtype, (000s)
  • Incidence of Diffuse large B-cell Lymphoma, (000s)
  • Diffuse large B cell lymphoma subtypes, (000s)
  • DLBCL by Ann Arbour Stage, (000s)
  • Incidence of Follicular Lymphoma (FL), (000s)
  • Follicular Lymphoma patients by FLIPI risk score, (000s)
  • FL patients by Ann Arbour Stage, (000s)
  • FL patients by predominant cell type, (000s)
  • Incidence of Mantle cell Lymphoma, total (000s)
  • Mantle Cell Lymphoma patients by Ann Arbour Stage, (000s)
  • Incidence of Burkitt’s Lymphoma, (000s)
  • Burkitts Lymphoma by Ann Arbour Stage, (000s)
  • Incidence of T-cell Lymphoma by main subtype, (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • USA Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Canada Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Canada Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • France Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • France Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Germany Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Germany Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Italy Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Italy Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Spain Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Spain Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • UK Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • UK Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Brazil Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Brazil Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Japan Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Japan Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • India Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • India Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • China Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • China Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Turkey Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Turkey Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Australia Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Australia Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Mexico Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Mexico Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Argentina Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Argentina Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Russia Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Russia Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
  • South Africa Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
  • South Africa Incidence of Non-Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States of America